Volume 23 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(6): 1056-1061
HU Minxuan, WANG Yufeng, LI Yuntao, JI Guozhong. Efficacy of mesenchymal stem cells in the treatment of fistulas in Crohn's disease: a meta-analysis[J]. Chinese Journal of General Practice, 2025, 23(6): 1056-1061. doi: 10.16766/j.cnki.issn.1674-4152.004064
Citation: HU Minxuan, WANG Yufeng, LI Yuntao, JI Guozhong. Efficacy of mesenchymal stem cells in the treatment of fistulas in Crohn's disease: a meta-analysis[J]. Chinese Journal of General Practice, 2025, 23(6): 1056-1061. doi: 10.16766/j.cnki.issn.1674-4152.004064
shu

Efficacy of mesenchymal stem cells in the treatment of fistulas in Crohn's disease: a meta-analysis

doi: 10.16766/j.cnki.issn.1674-4152.004064
  • 1.

    Department of General Practice, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China

Funds:

 M2022045

  • Received Date: 2024-11-18
    Available Online: 2025-09-04
    Abstract
  •   Objective  To systematically evaluate the effectiveness of mesenchymal stem cells (MSCs) in the treatment of fistulas in Crohn's disease (CD).  Methods  We searched CNKI, Wanfang, PubMed, Web of Science and other databases from inception to August 29, 2024. The eligible trials were independently evaluated and screened by two researchers. RevMan 5.4.1 and R 4.2.2 software were used to perform the meta-analysis.  Results  A total of 14 articles were included in the meta-analysis, all of which were randomized controlled trials (RCTs), encompassing a cumulative sample of 891 patients. results showed that compared with control groups, the fistula healing rate (FHR) induced by MSCs was higher in short-term (P=0.02), medium-term (P=0.02) and long-term (P=0.04) follow-up phases, while there was no statistically significant difference between the two groups in over-long-term (P=0.22). Using combined remission (Z=2.33, P=0.02) or clinical remission (Z=2.19, P=0.03) as the criteria for evaluating FHR, the experimental groups showed a higher FHR compared to the control group. Additionally, no heterogeneity was observed among subgroups (I2=0%, P=0.91). The use of MSCs derived from fat or bone marrow, autologous or allogeneic sources, medium or large doses achieved higher FHR compared to the control group. The FHR of injecting MSCs based on the size of the fistula was higher than that of the control group, while there was no statistically significant difference in the FHR between the two groups when treated in a single injection with a fixed dose.  Conclusion  The use of MSCs offers an emerging and effective approach for fistulizing CD treatment, which can lead to a higher rate of clinical and combined remission. More RCTs need to be performed in the future.

     

    • FullText(HTML)
  • loading
    • References(36)
  • [1]
    KÕVÁRI B, BÁTHORI Á, FRIEDMAN M S, et al. Histologic diagnosis of inflammatory bowel diseases[J]. Adv Anat Pathol, 2022, 29(1): 48-61. doi: 10.1097/PAP.0000000000000325
    [2]
    DOLINGER M, TORRES J, VERMEIRE S. Crohn's disease[J]. Lancet(London, England), 2024, 403(10432): 1177-1191.
    [3]
    PARIGI T L, D ' AMICO F, ABREU M T, et al. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting[J]. Lancet Gastroenterol Hepatol, 2023, 8(9): 853-859. doi: 10.1016/S2468-1253(23)00154-1
    [4]
    BROCHARD C, RABILLOUD M L, HAMONIC S, et al. Natural history of perianal Crohn's disease: long-term follow-up of a population-based cohort[J]. Clin Gastroenterol Hepatol, 2022, 20(2): e102-e110. doi: 10.1016/j.cgh.2020.12.024
    [5]
    郑丹萍, 何瑶. 《中国克罗恩病诊治指南(2023年·广州)》解读[J]. 中国中西医结合消化杂志, 2024, 32(8): 678-682.

    ZHENG D P, HE Y. Interpretation of the Chinese clinical practice guideline on the management of Crohn's disease (2023, Guangzhou)[J]. Chin J Integr Tradit West Med Dig, 2024, 32(8): 678-682.
    [6]
    SHEN B, KOCHHAR G S, RUBIN D T, et al. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the international ileal pouch consortium[J]. Lancet Gastroenterol Hepatol, 2022, 7(1): 69-95. doi: 10.1016/S2468-1253(21)00214-4
    [7]
    ADAMINA M, BONOVAS S, RAINE T, et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment[J]. Crohns Colitis, 2020, 14(2): 155-168. doi: 10.1093/ecco-jcc/jjz187
    [8]
    AGUILAR-MARTÍNEZ M D M, SÁNCHEZ-GUILLÉN L, BARBER-VALLES X, et al. Long-term evaluation of fistulotomy and immediate sphincteroplasty as a treatment for complex anal fistula[J]. Dis Colon Rectum, 2021, 64(11): 1374-1384. doi: 10.1097/DCR.0000000000001800
    [9]
    ZHIDU S, YING T, RUI J, et al. Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: challenges and opportunities[J]. Stem Cell Res Ther, 2024, 15(1): 266. doi: 10.1186/s13287-024-03885-z
    [10]
    LIAO H X, MAO X, WANG L, et al. The role of mesenchymal stem cells in attenuating inflammatory bowel disease through ubiquitination[J]. Front Immunol, 2024, 15: 1423069. DOI: 10.3389/fimmu.2024.1423069.
    [11]
    FAIRCLOTH T U, TEMPLE S, PARR R N, et al. Vascular endothelial growth factor secretion and immunosuppression are distinct potency mechanisms of human bone marrow mesenchymal stromal cells[J]. Stem cells, 2024, 42(8): 736-751. doi: 10.1093/stmcls/sxae040
    [12]
    SERRERO M, GRIMAUD F, PHILANDRIANOS C, et al. Long-term safety and efficacy of local microinjection combining autologous microfat and adipose-derived stromal vascular fraction for the treatment of refractory perianal fistula in Crohn's disease[J]. Gastroenterology, 2019, 156(8): 2335-2337.e2. doi: 10.1053/j.gastro.2019.01.032
    [13]
    WETWITTAYAKHLANG P, AL KHOURY A, HAHN G D, et al. The optimal management of fistulizing Crohn's disease: evidence beyond randomized clinical trials[J]. J Clin Med, 2022, 11(11): 3045. DOI: 10.3390/jcm11113045.
    [14]
    BARNHOORN M C, WASSER M N J M, ROELOFS H, et al. Long-term evaluation of allogeneic bone marrow-derived mesenchymal stromal cell therapy for Crohn's disease perianal fistulas[J]. J Crohns Colitis, 2020, 14(1): 64-70. doi: 10.1093/ecco-jcc/jjz116
    [15]
    GARCIA-OLMO D, GILABERTE I, BINEK M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn's disease: ADMIRE-CD phase 3 randomized controlled trial[J]. Dis Colon Rectum, 2022, 65(5): 713-720. doi: 10.1097/DCR.0000000000002325
    [16]
    GARCIA-OLMO D, HERREROS D, PASCUAL I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase Ⅱ clinical trial[J]. Dis Colon Rectum, 2009, 52(1): 79-86. doi: 10.1007/DCR.0b013e3181973487
    [17]
    GUADALAJARA H, HERREROS D, DE-LA-QUINTANA P, et al. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas[J]. Int J Colorectal Dis, 2012, 27(5): 595-600. doi: 10.1007/s00384-011-1350-1
    [18]
    LIGHTNER A L, PINEIRO A O, REESE J, et al. Treatment effect of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of fistulizing Crohn's disease are durable at 12 months[J]. Surgery, 2024, 175(4): 984-990. doi: 10.1016/j.surg.2023.11.007
    [19]
    LIGHTNER A L, REESE J, REAM J, et al. A phase IB/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of perianal fistulizing Crohn's disease[J]. Dis Colon Rectum, 2023, 66(10): 1359-1372. doi: 10.1097/DCR.0000000000002567
    [20]
    LIGHTNER A L, REESE J, REAM J, et al. A phase IB/IIA study of allogeneic, bone marrow-derived, mesenchymal stem cells for the treatment of refractory ileal-anal anastomosis and peripouch fistulas in the setting of Crohn's disease of the pouch[J]. Crohns Colitis, 2023, 17(4): 480-488. doi: 10.1093/ecco-jcc/jjac172
    [21]
    LIGHTNER A L, REESE J S, REAM J, et al. A phase IB/IIA study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of rectovaginal fistulizing Crohn's disease[J]. Surgery, 2024, 175(2): 242-249. doi: 10.1016/j.surg.2023.07.020
    [22]
    MOLENDIJK I, BONSING B A, ROELOFS H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease[J]. Gastroenterology, 2015, 149(4): 918-927.e6. doi: 10.1053/j.gastro.2015.06.014
    [23]
    PANÉS J, BOUMA G, FERRANTE M, et al. INSPECT: a retrospective study to evaluate long-term effectiveness and safety of darvadstrocel in patients with perianal fistulizing Crohn's disease treated in the ADMIRE-CD trial[J]. Inflamm Bowel Dis, 2022, 28(11): 1737-1745. doi: 10.1093/ibd/izab361
    [24]
    PANÉS J, GARCÍA-OLMO D, VAN ASSCHE G, et al. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn's disease[J]. Gastroenterology, 2018, 154(5): 1334-1342.e4. doi: 10.1053/j.gastro.2017.12.020
    [25]
    PANÉS J, GARCÍA-OLMO D, VAN ASSCHE G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial[J]. Lancet, 2016, 388(10051): 1281-1290. doi: 10.1016/S0140-6736(16)31203-X
    [26]
    SERCLOVA Z, GARCIA-OLMO D, CHEN S T, et al. OP18 Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn's disease: results from the global ADMIRE-CD Ⅱ phase 3 study[J]. J Crohns Colitis, 2024, 18(Supplement_1): i34-i35. DOI: 10.1093/ecco-jcc/jjad212.0018.
    [27]
    ZHOU C, LI M, ZHANG Y, et al. Autologous adipose-derived stem cells for the treatment of Crohn's fistula-in-ano: an open-label, controlled trial[J]. Stem Cell Res Ther, 2020, 11(1): 124. doi: 10.1186/s13287-020-01636-4
    [28]
    张敏, 王晨晓, 石荣, 等. 间充质干细胞治疗肛周瘘管型克罗恩病临床疗效的Meta分析[J]. 福建中医药, 2023, 54(3): 50-59.

    ZHANG M, WANG C X, SHI R, et al. Meta-analysis of the clinical efficacy of mesenchymal stem cells in the treatment of perianal fistula-type Crohn's disease[J]. Fujian Journal of Traditional Chinese Medicine, 2023, 54(3): 50-59.
    [29]
    CHENG F, HUANG Z, WEI W, et al. Efficacy and safety of mesenchymal stem cells in the treatment of perianal fistulas in Crohn's disease: a meta-analysis of randomized controlled trials[J]. Rev Esp Enferm Dig, 2023. DOI: 10.17235/reed.2023.9213/2022.
    [30]
    CAO Y, SU Q, ZHANG B, et al. Efficacy of stem cells therapy for Crohn's fistula: a meta-analysis and systematic review[J]. Stem Cell Res Ther, 2021, 12(1). DOI: 10.1186/s13287-020-02095-7.
    [31]
    EMAN A S, SHAJI S. Is MRI healing the target in treating perianal fistulizing Crohn's disease?[J]. Eur J Gastroenterol Hepatol, 2020, 32(2): 137-138. doi: 10.1097/MEG.0000000000001575
    [32]
    AZZAM N, ALHARBI O, ALMADI M, et al. Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn's disease treated with antitumor necrosis factor-alpha agents based on Parks ' classification[J]. Eur J Gastroenterol Hepatol, 2020, 32(2): 187-192. doi: 10.1097/MEG.0000000000001634
    [33]
    CABALZAR-WONDBERG D, TURINA M, BIEDERMANN L, et al. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: a case series[J]. Colorectal Dis, 2021, 23(6): 1444-1450. doi: 10.1111/codi.15587
    [34]
    叶钢, 李玉红. 干细胞在周围神经再生中的应用研究进展[J]. 中华全科医学, 2019, 17(10): 1736-1741, 1772. doi: 10.16766/j.cnki.issn.1674-4152.001044

    YE G, LI Y H. Advances in the application of stem cells in peripheral nerve regeneration[J]. Chinese Journal of General Practice, 2019, 17(10): 1736-1741, 1772. doi: 10.16766/j.cnki.issn.1674-4152.001044
    [35]
    CARVELLO M, LIGHTNER A, YAMAMOTO T, et al. Mesenchymal stem cells for perianal Crohn's disease[J]. Cells, 2019, 8(7): 764. DOI: 10.3390/cells8070764.
    [36]
    WANG H, JIANG H Y, ZHANG Y X, et al. Mesenchymal stem cells transplantation for perianal fistulas: a systematic review and meta-analysis of clinical trials[J]. Stem Cell Res Ther, 2023, 14(1): 103. doi: 10.1186/s13287-023-03331-6
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (12) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return